Neuvogen Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
19
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$5M
- Investors
-
2
Neuvogen General Information
Description
Developer of therapeutic vaccines designed for cancer treatment by harnessing the full power of a patient's immune system. The company is applying a systems approach to develop medicinal whole-cell cancer vaccines that have tumor-associated antigens, enabling oncologists to provide cancer-specific treatment customized to each patient's condition.
Contact Information
Website
neuvogen.comCorporate Office
- 11095 Flintkote Avenue
- Suite C
- San Diego, CA 92121
- United States
Corporate Office
- 11095 Flintkote Avenue
- Suite C
- San Diego, CA 92121
- United States
Neuvogen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC | 04-Jul-2024 | $5M | Completed | Clinical Trials - General | ||
| 1. Early Stage VC (Series 1) | 04-Dec-2017 | Completed | Clinical Trials - General |
Neuvogen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Neuvogen Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Neuvogen Patents
Neuvogen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230000963-A1 | Tumor cell vaccines | Inactive | 02-Jun-2021 | ||
| US-20250134977-A1 | Tumor cell vaccines | Pending | 02-Jun-2021 | ||
| WO-2022256360-A1 | Tumor cell vaccines | Inactive | 02-Jun-2021 | ||
| US-20220133869-A1 | Breast cancer tumor cell vaccines | Inactive | 02-Nov-2020 | ||
| US-20250332235-A1 | Breast cancer tumor cell vaccines | Pending | 02-Nov-2020 | A61K39/0011 |
Neuvogen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Neuvogen Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alafi Capital Company | Venture Capital | Minority | ||
| Bering Capital | Venture Capital | Minority |
Neuvogen FAQs
-
When was Neuvogen founded?
Neuvogen was founded in 2016.
-
Where is Neuvogen headquartered?
Neuvogen is headquartered in San Diego, CA.
-
What is the size of Neuvogen?
Neuvogen has 19 total employees.
-
What industry is Neuvogen in?
Neuvogen’s primary industry is Drug Discovery.
-
Is Neuvogen a private or public company?
Neuvogen is a Private company.
-
What is Neuvogen’s current revenue?
The current revenue for Neuvogen is .
-
How much funding has Neuvogen raised over time?
Neuvogen has raised $15M.
-
Who are Neuvogen’s investors?
Alafi Capital Company and Bering Capital have invested in Neuvogen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
